257 related articles for article (PubMed ID: 38633308)
21. Next-generation treatments: Immunotherapy and advanced therapies for COVID-19.
Arevalo-Romero JA; Chingaté-López SM; Camacho BA; Alméciga-Díaz CJ; Ramirez-Segura CA
Heliyon; 2024 Mar; 10(5):e26423. PubMed ID: 38434363
[TBL] [Abstract][Full Text] [Related]
22. SARS-CoV-2 infection in kidney transplant recipients: Experience of the italian marche region.
Maritati F; Cerutti E; Zuccatosta L; Fiorentini A; Finale C; Ficosecco M; Cristiano F; Capestro A; Balestra E; Taruscia D; Vivarelli M; Donati A; Perna GP; Giacometti A; Tavio M; Onesta M; Di Sante L; Ranghino A
Transpl Infect Dis; 2020 Oct; 22(5):e13377. PubMed ID: 32573895
[TBL] [Abstract][Full Text] [Related]
23. Impaired Immune Response to SARS-CoV-2 Vaccination in Dialysis Patients and in Kidney Transplant Recipients.
Kolb T; Fischer S; Müller L; Lübke N; Hillebrandt J; Andrée M; Schmitz M; Schmidt C; Küçükköylü S; Koster L; Kittel M; Weiland L; Dreyling KW; Hetzel G; Adams O; Schaal H; Ivens K; Rump LC; Timm J; Stegbauer J
Kidney360; 2021 Sep; 2(9):1491-1498. PubMed ID: 35373105
[TBL] [Abstract][Full Text] [Related]
24. Effectiveness, Immunogenicity and Harms of Additional SARS-CoV-2 Vaccine Doses in Kidney Transplant Recipients: A Systematic Review.
Hausinger RI; Bachmann Q; Crone-Rawe T; Hannane N; Monsef I; Haller B; Heemann U; Skoetz N; Kreuzberger N; Schmaderer C
Vaccines (Basel); 2023 Apr; 11(4):. PubMed ID: 37112775
[TBL] [Abstract][Full Text] [Related]
25. Determinants of Immune Response to Anti-SARS-CoV-2 mRNA Vaccines in Kidney Transplant Recipients: A Prospective Cohort Study.
Magicova M; Zahradka I; Fialova M; Neskudla T; Gurka J; Modos I; Hojny M; Raska P; Smejkal P; Striz I; Viklicky O
Transplantation; 2022 Apr; 106(4):842-852. PubMed ID: 34999659
[TBL] [Abstract][Full Text] [Related]
26. Acute Kidney Injury in a Predominantly African American Cohort of Kidney Transplant Recipients With COVID-19 Infection.
Shrivastava P; Prashar R; Khoury N; Patel A; Yeddula S; Kitajima T; Nagai S; Samaniego M
Transplantation; 2021 Jan; 105(1):201-205. PubMed ID: 33093403
[TBL] [Abstract][Full Text] [Related]
27. Long-term shedding of viable SARS-CoV-2 in kidney transplant recipients with COVID-19.
Benotmane I; Risch S; Doderer-Lang C; Caillard S; Fafi-Kremer S
Am J Transplant; 2021 Aug; 21(8):2871-2875. PubMed ID: 33961334
[TBL] [Abstract][Full Text] [Related]
28. COVID-19 early curative treatments in kidney transplant recipients: is it really reasonable at the Omicron era?
Tamzali Y; Lundy A; Bleibtreu A; Cazenave M; Mohammadou I; Arzouk N; Galichon P; Marot S; Junot H; Barrou B; Pourcher V; Tourret J
Nephrol Ther; 2023 Nov; 19(6):491-496. PubMed ID: 37915200
[TBL] [Abstract][Full Text] [Related]
29. Management of COVID-19 in Kidney Transplant Recipients: A Single-Center Case Series.
Marbun MBH; Saragih RJ; Andina T
Int J Nephrol; 2022; 2022():9636624. PubMed ID: 36035233
[TBL] [Abstract][Full Text] [Related]
30. Antibody and T Cell Response to SARS-CoV-2 Messenger RNA BNT162b2 Vaccine in Kidney Transplant Recipients and Hemodialysis Patients.
Bertrand D; Hamzaoui M; Lemée V; Lamulle J; Hanoy M; Laurent C; Lebourg L; Etienne I; Lemoine M; Le Roy F; Nezam D; Plantier JC; Boyer O; Guerrot D; Candon S
J Am Soc Nephrol; 2021 Sep; 32(9):2147-2152. PubMed ID: 34112706
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of the Humoral and Cellular Immune Response Post COVID-19 Infection in Kidney Transplant Recipients.
Bensaid K; Lamara Mahammed L; Habchi K; Saidani M; Allam I; Djidjik R
J Clin Med; 2023 Jun; 12(12):. PubMed ID: 37373595
[TBL] [Abstract][Full Text] [Related]
32. Humoral and cellular immune response to SARS-CoV-2 mRNA BNT162b2 vaccine in pediatric kidney transplant recipients compared with dialysis patients and healthy children.
Gulmez R; Ozbey D; Agbas A; Aksu B; Yildiz N; Uckardes D; Saygili S; Yilmaz EK; Yildirim ZY; Tasdemir M; Kiykim A; Cokugras H; Canpolat N; Nayir A; Kocazeybek B; Caliskan S
Pediatr Nephrol; 2023 Jul; 38(7):2199-2208. PubMed ID: 36459243
[TBL] [Abstract][Full Text] [Related]
33. Global emerging Omicron variant of SARS-CoV-2: Impacts, challenges and strategies.
Dhama K; Nainu F; Frediansyah A; Yatoo MI; Mohapatra RK; Chakraborty S; Zhou H; Islam MR; Mamada SS; Kusuma HI; Rabaan AA; Alhumaid S; Mutair AA; Iqhrammullah M; Al-Tawfiq JA; Mohaini MA; Alsalman AJ; Tuli HS; Chakraborty C; Harapan H
J Infect Public Health; 2023 Jan; 16(1):4-14. PubMed ID: 36446204
[TBL] [Abstract][Full Text] [Related]
34. Short and Long-Term Outcomes of Kidney Transplant Recipients Diagnosed With COVID-19 Infection: A Single-Center Observational Study.
Defelice G; Giusti S; Jeon H; Killackey M; Paramesh A; Vijay A
Cureus; 2022 Nov; 14(11):e31375. PubMed ID: 36523681
[TBL] [Abstract][Full Text] [Related]
35. Assessing antiviral treatment efficacy and risk factors for severe COVID-19 in kidney transplant recipients during the Omicron subvariant-dominant period: a retrospective study.
Sakaguchi T; Mitsuke A; Osako Y; Yamada Y; Takeyama H; Ogawa R; Takahashi K; Hirohata Y; Yamamoto S; Arima J; Fukumoto W; Sugita S; Inoguchi S; Matsushita R; Yoshino H; Tatarano S; Enokida H
BMC Nephrol; 2024 Apr; 25(1):124. PubMed ID: 38589827
[TBL] [Abstract][Full Text] [Related]
36. Weak antibody response to three doses of mRNA vaccine in kidney transplant recipients treated with belatacept.
Chavarot N; Morel A; Leruez-Ville M; Vilain E; Divard G; Burger C; Serris A; Sberro-Soussan R; Martinez F; Amrouche L; Bererhi L; Lanternier F; Legendre C; Zuber J; Anglicheau D; Scemla A
Am J Transplant; 2021 Dec; 21(12):4043-4051. PubMed ID: 34431207
[TBL] [Abstract][Full Text] [Related]
37. Intensity of mycophenolate mofetil treatment is associated with an impaired immune response to SARS-CoV-2 vaccination in kidney transplant recipients.
Kantauskaite M; Müller L; Kolb T; Fischer S; Hillebrandt J; Ivens K; Andree M; Luedde T; Orth HM; Adams O; Schaal H; Schmidt C; Königshausen E; Rump LC; Timm J; Stegbauer J
Am J Transplant; 2022 Feb; 22(2):634-639. PubMed ID: 34551181
[TBL] [Abstract][Full Text] [Related]
38. Humoral Responses in the Omicron Era Following 3-Dose SARS-CoV-2 Vaccine Series in Kidney Transplant Recipients.
McEvoy CM; Hu Q; Abe KT; Yau K; Oliver MJ; Levin A; Gingras AC; Hladunewich MA; Yuen DA
Transplant Direct; 2023 Jan; 9(1):e1401. PubMed ID: 36518793
[TBL] [Abstract][Full Text] [Related]
39. Outcomes of COVID‑19 in hospitalized kidney and liver transplant recipients: a single‑center experience.
Ślusarczyk A; Tracz A; Gronkiewicz M; Jureczko L; Bączkowska T
Pol Arch Intern Med; 2021 Nov; 131(11):. PubMed ID: 34351090
[TBL] [Abstract][Full Text] [Related]
40. Humoral and cellular immune response and the safety of third SARS-CoV-2 mRNA vaccine with longer interval after the second vaccination in kidney transplant recipients.
Takai S; Nishida H; Ito H; Fukuhara H; Nawano T; Narisawa T; Kanno H; Yagi M; Yamagishi A; Sakurai T; Naito S; Kato T; Morikane K; Tsuchiya N
Front Immunol; 2022; 13():1050211. PubMed ID: 36532067
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
